our EIS fund today

technology overview

Every member of our development team is the graduate of a top Indian IT University. We hand pick the brightest minds, and then train them in the latest technologies and techniques. Each member of our spends time working in two or more disciplnes, to give them a broader understanding of the total technology stack. Over the years we have built mobile apps, CRM’s, social media networks, intranets, project management tools, stock management systems, HR analytics, employee communications, and many more. We have particular strengths in recruitment, HR, talent, employer branding, communications, and scientific applications, however we have the analytical and project delivery skills to work in nearly any area or vertical.

technology brochure

If you would like further details and would like to read our brochure you can request to download it below:

o2h EIS fund IM

o2h technology benefits

We are a not just techies, we are pioneers in our own right. We have build, run and sold many of our own companies, products and services over the years, and continue to invest back into the technology and scientific community through funding and mentorship programs.

Low Cost Model

European / Indian Project Management

Access To Our Tech Investor Network

Full Turnkey Solution Service

Access To Advice And Support

methodology

Using Agile Methodology we ensure continues customer satisfy software delivery

technology

Using Agile Methodology we ensure continuous customer satisfactory software delivery

tech team

Cengiz Tarhan

Cengiz set up FreeMedic PLC in 1993 which he grew over 25 years and is now known as UCL Business PLC, one of the most proli c and successful technology groups in the UK serving UCL and its associated partner hospitals. Over those years Cengiz was directly involved in many licenses and spinouts including PolyMASC Pharmaceuticals PLC, one of the rst university spin-outs to oat on the London AIM in 1995, Medic to Medic Ltd which was sold to Informa PLC in 2005 and Stanmore Implants Worldwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. More recently UCLB has been at the vanguard of creating the most promising cancer and gene therapy biotechs in the UK including three

Connect on Linkedin

recent projects

Using Agile Methodology we ensure continuous

track our development

we use a multitude of technologies and process to keep each other informed

Mattermost

A new way for organisations to drive their company values

Jira

A new way for organisations to drive their company values

BitBucket

A new way for organisations to drive their company values

Slack

A new way for organisations to drive their company values

ventures news

31 Jan 2019

o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h
Therapeutics Fund” an early stage SEIS and/or EIS fund backing biotech therapeutic and related AI
opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.

The investment focus of the fund will be therapeutic drug opportunities or technologies that enable drug discovery with an emphasis on Artificial Intelligence (AI). The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca, and is home
to many biotech companies some of which have subsequently been snapped up by large pharmaceutical companies.

Large pharmaceutical companies have been closing down research centers globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing up the prices for the best science and providing earlier exit opportunities. The team at o2h have access to the most exciting scientific ideas through its live working relationships fostered over many years working as a discovery services company. This gives us far earlier access than competitors to the most promising companies.

Early stage companies often need more than just money, o2h Ventures has built a unique integrated model for early stage companies which includes the possibility of offering companies incubation in its o2h SciTech Park, in Cambridge, UK, and/or the option to jump-start their research activity from o2h Discovery in Ahmedabad, India.

[gallery size="full" columns="2" link="none" ids="1248,1249"]

The Old Mill Warehouse - Incubation and co-working spaces and Hauxton House - o2h Ventures Global HQ.

The fund is structured to be S/EIS compliant providing generous income, inheritance and capital
gains tax breaks for UK tax payers.

Investors may download the investment memorandum at www.o2h.com/ventures

About o2h:

o2h seeds new ideas in science, technology and social enterprise. We work across boundaries and take a
collaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring
these ideas to life. o2h is co-located in Ahmedabad, India and in Cambridge UK and has 6 verticals covering
Ventures, Co-work, Discovery Services, Therapeutics, Technology, and Community. Visit- www.o2h.com for more details.

Sunil Shah, CEO of o2h commented “We are really excited to launch the o2h ventures therapeutics fund. We see great deal flow through our hot network which is an accumulation of over 15 years of providing research services to this sector. The EIS benefits are a great way to invest in these fledgling businesses and access great British
innovation in therapeutics whilst mitigating the risk through the tax benefits. We look forward to making our first investment in early 2019.

Contact:
Sunil Shah, Partner at o2h Ventures Limited
www.o2h.com/ventures

Mail- invest@o2h.com

18 Oct 2018

“Investment will accelerate the delivery of significantly improved therapeutic treatments and quality of life for people living with diabetes”

Cambridge, UK., 10 September 2018: Arecor Ltd (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.

This £6.0 million equity investment into Arecor was led by leading UK institutional investors, Calculus Capital, Downing Ventures, and Albion Capital with significant participation from Arecor’s existing investors. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.

Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens and offer greater control of blood glucose to diabetes patients, which is key to improving outcomes and quality of life.

This pipeline includes:-

@ Proprietary formulations of analogues that are ultra-rapid acting and more closely match a healthy body’s physiological response to blood glucose, leading to better blood glucose (sugar) control – currently a significant challenge

@ Highly concentrated rapid acting optimised for the next generation of body-worn miniaturised delivery devices, including the artificial pancreas

@ Stable aqueous ready to use used in an emergency to treat severe hypoglycaemia and enabling future use in bi-hormonal artificial pancreas systems

These programmes will be progressed through development to demonstrate improved product profiles and health outcomes in human clinical trials.  In addition to these clinical programmes, the investment will allow Arecor to progress its pre-clinical pipeline of diabetes combination products, as well as a range of additional superior biotherapeutics addressing critical unmet needs in key disease areas.

The management of diabetes is one of the major global health challenges.  Indeed, the International Diabetes Federation (“IDF”) estimates that there are nearly half a billion (425 million) people currently living with diabetes around the world* and the IDF further estimates that if the global direct and indirect healthcare costs from diabetes are included, the economic impact of diabetes exceeds $1trillion**.

International Diabetes Federation. IDF Diabetes Atlas, 8th edition. International Diabetes Federation, 2017. Available at: http://www.diabetesatlas.org/

** Bommer C., Heesemann E., Sagalova V., et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 2017; 5: 423-30.

The improved products, therapeutic pathways and personalised control that Arecor’s products can enable, will make a significant contribution to addressing this challenge.   Arecor will be taking its product portfolio into clinical development itself, however, the Company will ultimately look to partner with specialist diabetes companies for late stage clinical studies and global market access.

The Company, which was originally based on unique protein chemistry technology and insights spun out from Unilever, has refined and developed these into the ArestatTM formulation technology platform. This platform has been used extensively to improve the solution properties of numerous protein, anti-body, vaccine and peptide formulations both in collaboration with pharmaceutical partners, as well as for Arecor’s own pipeline.  Arecor has established a proven track record in applying this technology platform to deliver superior biopharmaceutical product profiles across a broad range of therapeutic areas.

Dr Sarah Howell, Chief Executive Officer at Arecor, commented: “We are delighted to have secured the investment that we need to progress our lead diabetes programmes through the key stages of clinical development.  With diabetes reaching epidemic proportions worldwide and with close to half a billion people living with the condition today, the opportunity of advancing our diabetes products into human clinical trials and their potential to significantly improve the treatment of this debilitating disease, represents a very exciting and ground-breaking proposition”.

Alexander Crawford, Investment Director, Calculus Capital, added: Arecor is applying its unique and highly regarded reformulation technology which will help transform the growing diabetes market. As lead investor, we believe this is an exciting new phase from Arecor in the development of their technology and strong growth potential.”

Dr Christoph Ruedig, Partner, Albion Capital, said: “We have followed Arecor for some time and are excited by the societal value of its fast onset, short duration action. Its technology is highly differentiated and the Company is leading the sector in the area of stabilising liquid formulations for injectable drugs. We look forward to working with the strong leadership team to bring this extraordinary proposition to fruition and in doing so, aid many diabetic patients across the UK and beyond.”

Richard Lewis, Investment Director, Downing Ventures, concluded: “As an investment opportunity, Arecor combines a solid and high margin technology business alongside a proprietary product offering that fulfils major unmet medical need.  As a result, we believe that the diabetes pipeline should successfully attract quality international commercial partners. ”

Arecor is one of o2h Ventures’ investment.

25 May 2018

Stemnovate which is advancing 'organ on chip' technology has closed its seed investment round with a team of eight angels led by team of o2h ventures, whose co-founder Sunil Shah is joining the board as chairman.Stemnovate specialises in stem cell research, cellular differentiation and microengineering. Its 'liver on a chip' technology has exciting potential for pre-clinical hepatotoxicity testing, replicating the microarchitecture and functions of the human liver and taking account of variation in patient's individual genetic backgrounds.

Mr Shah, who is an MBA from Cambridge University is a serial entrepreneur who co-founded two companies in information technology and life sciences sector O2h ventures involves discovery services and collaboration, seeding drug discovery, academic in-licensing and bio-technology incubation.He said "current models for screening new drugs for liver toxicity are not predictive,there is an urgent need for the reliable screening technology before millions are invested into a clinical trial only to fail due to liver toxicity".

For more information- Stemnovate Secure....